Vasonatrin Peptide (VNP)
| 中文名稱 | Vasonatrin Peptide (VNP) |
|---|---|
| 中文同義詞 | H-GLY-LEU-SER-LYS-GLY-CYS-PHE-GLY-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR-OH((DISULFIDE BRIDGE: CYS6-CYS22);心鈉素C型利鈉肽嵌合多肽VASONATRIN PEPTIDE (VNP) |
| 英文名稱 | Vasonatrin Peptide (VNP) |
| 英文同義詞 | GLY-LEU-SER-LYS-GLY-CYS-PHE-GLY-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR ((DISULFIDE BRIDGE: CYS6-CYS22);H-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH;L-Tyrosine, glycyl-L-leucyl-L-seryl-L-lysylglycyl-L-cysteinyl-L-phenylalanylglycyl-L-leucyl-L-lysyl-L-leucyl-L-α-aspartyl-L-arginyl-L-isoleucylglycyl-L-seryl-L-methionyl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-asparaginyl-L-seryl-L-phenylalanyl-L-arginyl-, cyclic (6→22)-disulfide;Vasonatrin Peptide (VNP) Trifluoroacetate;Vasonatrin Peptide (VNP) |
| CAS號 | 141676-35-9 |
| 分子式 | C124H198N36O36S3 |
| 分子量 | 2865.34 |
| EINECS號 | |
| 相關(guān)類別 | |
| Mol文件 | 141676-35-9.mol |
| 結(jié)構(gòu)式 |  |
Vasonatrin Peptide (VNP) 性質(zhì)
| 密度 | 1.47±0.1 g/cm3(Predicted) |
|---|---|
| 序列 | Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bridge: Cys6-Cys22) |
Natriuretic peptide receptors
Vasonatrin peptide binds with both natriuretic peptide receptor A and B, but with a preference for B. VNP-stimulated cGMP is 11-fold greater in NPRB than NPRA.
The high-fat diet-fed streptozotocin-induced diabetic Sprague-Dawley rats are subjected to ischemia-reperfusion operation. VNP treatment (100 g/kg iv, 10 min before reperfusion) significantly improved the instantaneous first derivation of left ventricle pressure (LV dP/dtmax) and LV systolic pressure and reduced LV end-diastolic pressure, apoptosis index, caspase-3 activity, plasma creatine kinase (CK), and lactate dehydrogenase (LDH) activities. Treatment hypoxia-induced pulmonary hypertension (HPH) with Vasonatrin peptide for 1 week significantly reduceS mean pulmonary arterial pressure, pulmonary vascular resistance, RVH and muscularization of the pulmonary arteries. Acute intravenous administration of 50 microg/kg Vasonatrin peptide significantly ameliorates pulmonary haemodynamics in HPH rats.
安全信息
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2023/03/20 | HY-P1556 | Vasonatrin Peptide (VNP)
Vasonatrin Peptide (VNP) | 141676-35-9 | 500μg | 2000元 |
| 2023/03/20 | HY-P1556 | Vasonatrin Peptide (VNP)
Vasonatrin Peptide (VNP) | 141676-35-9 | 1mg | 3600元 |